Remissions of haematological malignancies have been reported after allo-SCT, despite donor cell rejection, suggesting that sustained allogeneic engraftment is not mandatory to obtain a lasting anti-tumour effect. To evaluate the potential benefit from transient post-allo-SCT alloreactivity, we took advantage of the Socie´teF ranc¸aise de Greffe de Moe¨lle et The´rapie Cellulaire (SFGM-TC) registry to colligate 14 patients with an efficient and long-lasting allogeneic (GVL) effect after allo-SCT for haematological malignancies, despite transient or absent engraftment. None received a second allogeneic graft after autologous recovery. The median duration of remission after autologous reconstitution was 118 (12À252) months. Although we cannot exclude the possibility that some patients were cured before allo-SCT, this retrospective analysis does strongly suggest that an efficient GVL effect can be observed without sustained donor engraftment, and that the transient presence of donor T cells might be sufficient to induce a powerful GVL effect.
Introduction
The initial rationale for carrying out allogeneic haematopoietic SCT (allo-SCT) was the replacement of a defective BM. This therapeutic option has been extended to haematological malignancies with the evidence that immune competent cells supplied with the haematopoietic graft mediate a strong anti-tumour effect, generally termed a GVL effect. As such, allo-SCT has become a very efficient, albeit potentially toxic, form of adoptive immunotherapy and an important tool in the therapeutic arsenal to treat haematological malignant diseases. 1 Several studies have established that donor T cells are the major players with respect to the GVL effect. Carrying out a T-celldepleted allogeneic transplantation 2 as well as functional blocking of T cells by a monoclonal IL-2-receptor Ab for instance, 3 leads to an increased rate of relapse in allografted patients. Furthermore, clinical studies have established that the use of donor lymphocyte infusion (DLI) can induce a durable remission in patients who experienced a relapse after receiving a transplant for CML and in some patients with acute leukaemia. [4] [5] [6] Ballester et al. 7 described a graftvs-myeloma effect with DLI from an allogeneic donor after high-dose therapy supported by autologous stem cell transplant rescue. GVHD arose in six of seven patients and spontaneously resolved after autologous engraftment; five of six patients experiencing GVHD survived for a long time after the transplant procedure.
Graft failure, a scarce event in the absence of graft T-cell depletion and the use of a non-myeloablative conditioning regimen, is frequently associated with relapse. 8 Several case reports mentioned the achievement of clinical remission of haematological malignancies, despite donor marrow rejection and documented host-derived haematopoietic reconstitution after myeloablative as well as non-myeloablative conditioned allo-SCT. [9] [10] [11] [12] [13] In 2000, Brunstein et al.
14 reported on 10 patients who underwent allo-SCT for CML and developed autologous reconstitution, of which two had sustained remissions. These cases suggested that sustained allogeneic engraftment is not absolutely necessary to obtain a long-lasting anti-tumour effect. A total of 41 patients belonging to 13 centres were identified with a 31-year (3-57) median age; they were grafted for acute leukaemia (n ¼ 19), CML (n ¼ 8), myelodysplastic syndrome (7), juvenile myelomonocytic leukaemia (2), non-Hodgkin lymphoma (2), multiple myeloma (2) and chronic lymphoid leukaemia (CLL ¼ 1). In total, 14 patients received a T-cell-depleted allograft; 34 patients received a myeloablative conditioning regimen; and 7 patients a reduced intensity conditioning regimen.
Full autologous recovery was considered as documented when chimerism data in marrow aspirates or in blood samples exhibited 100% recipient markers. Chimerism analyses were carried out by amplification (PCR) of polymorphic DNA sequences for patients 1-4, 12 and 13. For patient 11, chimerism analyses were assessed using a FISH technique. The details regarding techniques used for the chimerism analyses in the other cases were not available.
Results
A total of 27 of the 41 patients died 3-6 months after nonengraftment or graft rejection. Among these 27 patients the main cause of death was relapse of the original disease (n ¼ 22) or severe, prolonged pancytopenia with fatal infection (n ¼ 5). Only 14 patients achieved autologous reconstitution with a long-lasting CR and constituted the cohort of this study. The main patients' characteristics are summarized in Table 1 . All patients with acute leukaemia or myelodysplastic syndrome were grafted in CR. The three CML patients were grafted in chronic phase. Two patients underwent allo-SCT in the presence of progressive disease: one patient in accelerated phase of CML and one patient with chronic lymphoid leukaemia in PR. Preparative regimens were myeloablative in nine cases and five patients received a T-cell-depleted graft without any post-transplant immunosuppression.
Four patients had transient documented donor engraftment as evidenced by donor chimerism from 3 to 20 months. All patients with transient engraftment had received a myeloablative regimen, followed by the reinjection of a T-cell-depleted graft in two cases. No donor engraftment was ever documented in the 10 remaining patients; autologous haematopoiesis recovered spontaneously before day 40 post-allo-SCT for eight patients; two patients received an autologous rescue on days 30 and 37 post-allo-SCT, respectively. Two patients conditioned with myeloablative regimen also received a DLI: patient 3 before, and patient 12 after the occurrence of documented complete autologous reconstitution. These patients displayed persistent autologous haematopoiesis without any documentation of donor engraftment. Median CR duration after autologous reconstitution was 118 (12-252) months (Table 1) . Five patients have relapsed; the earliest relapse occurred at 12 months and the latest 199 months after transplantation. Despite persistent cytogenetic and molecular response, IFN therapy was administered in two CML patients (1 and 4) for 6 and 30 months after autologous reconstitution, respectively. Patient 1 has remained in molecular remission for 103 months before the occurrence of a cytogenetic relapse. Patient 4 also received imatinib for 4 years after interruption of IFN therapy because of neurological toxicity, whereas remaining in constant molecular remission; both remaining CML patients (2 and 3) received no further treatment after autologous reconstitution; these three patients remained in molecular remission.
Ultimately nine patients have potentially gained the benefit of potential transient alloreactivity after allo-SCT, after receiving a T cell-depleted graft in three cases. Six patients remained in persistent unmaintained prolonged remission after documented autologous reconstitution, whereas three patients have received additional immunotherapy, IFN in one case and DLI in two cases.
Discussion
The purpose of our study was to evaluate a group of patients with transient or no engraftment, who developed sustained autologous reconstitution without relapse of their original haematological malignancy. This situation seemed very rare and despite the screening of a large database, we only identified a small number of patients meeting these criteria (14 out of 10 887 recipients, 0.12%). Most of the patients in our database were grafted before 2005, before the large development of non-myeloablative conditioning regimens. The 41 patients with graft rejection or nonengraftment after allo-SCT belong to 13 among 40 French centres reporting to the SFGM-TC, and the long-lasting remissions were observed in 14 patients belonging to eight centres. In our centre, we have identified four patients of the 14 presented in this study. It seems as a disproportionate representation of this rare situation in some SFGM-TC centres. We can suppose that the events 'graft rejection' or 'non-engraftment' were sometimes recorded as 'relapse' in the registry, especially when it occurs during the first 6 months after allo-SCT, before the clear documentation of non-engraftment. This could partially explain the differences in the recruitment between the 40 centres and could represent a bias in our study.
A few cases have been reported earlier, but only two short series described similar long-lasting remissions after graft failure and autologous reconstitution.
9,14 A retrospective study by Brunstein et al. included 10 CML patients who underwent myeloablative conditioning before allo-SCT; 5 received a T cell-depleted graft and no patient received additional DLI. The non-malignant autologous reconstitution persisted for a median of 11.5 months (range 3-41) and the CR was achieved for a median of 12 months (range 6-40). A prospective study by Dey et al.
14 included 22 recipients with diverse advanced haematological malignancies (Hodgkin lymphoma, AML, ALL, chronic lymphoid leukaemia, multiple myeloma and non-Hodgkin lymphoma). The preparative regimen was non-myeloablative, and prophylactic DLIs were given to all patients with mixed chimerism and no evidence of GVHD. Patients were eligible for prophylactic DLI in the absence of clinically evident GVHD on day þ 35. In the case of disease progression, additional DLIs with higher CD3 þ T-cells were infused. Nine achieved anti-tumour response, despite the loss of donor graft and six remained alive 2.5-5.5 years after allo-SCT (four in continuous CR). This last study, designed to maximize the allogeneic GVL effect, is difficult to compare with our study. Nevertheless, the duration of non-malignant autologous reconstitution in these two studies is much shorter (11.5 months) than in our cohort of patients (118 months).
Several of the patients we analysed, with a follow-up of 10 years, are probably cured. This is a strong argument suggesting the presence of efficient alloreactivity. Two patients of our cohort, grafted with an advanced disease, experienced a relapse suggesting, arguably as expected, that such transient alloreactivity is more likely to be efficient in cases with a low tumour burden.
One cannot exclude the possibility that a proportion of the 14 patients in long-term remission after allo-SCT and autologous reconstitution were in fact cured before allo-SCT or with the myeloablative conditioning regimen, as observed after autologous transplantation. Nevertheless, for patients with CML (four patients in our cohort, three in continuous remission) or with myelodysplastic syndrome (four patients, three in continuous remission) the chance of achieving a cure without any additional allogeneic effect seems quite improbable.
Efficient long-term anti-tumour responses stemming from transient allo-SCT engraftment could result from several non-exclusive mechanisms, some of them not directly implying T-cell-mediated alloreactivity. Van Leeuwen et al. 15 have reported the persistence of non-malignant host-type cells after myeloablative regimens and allo-SCT for children with leukaemia. The results suggest that neither persistence of mature host-type T cell nor the persistence of host-type BM-derived APCs, are associated with a significant decrease in the GVL effect after allo-SCT. These findings might corroborate the long-lasting remission observed in our study.
It has also been reported in animal models that human allogeneic T-cell clones can induce anti-tumour effects in the absence of donor cell survival. 16 Anti-viral and antitumour efficacy of allogeneic anti-EBV CTL have been described, despite evidence for early rejection of the infused cells. [17] [18] [19] Several authors have suggested that a GVL effect could be promoted by the host-vs-graft immune response associated with graft rejection. Compatible with such a mechanism is the observation that patients who reject their graft have increased numbers of recipient-derived CD8 þ T cells, recipient-derived anti-donor IL-2-producing cells and cytotoxic T-cell responses on day þ 35 postallo-SCT. [20] [21] [22] [23] [24] To test this hypothesis, they built a murine model in which spontaneous graft rejection or graft rejection induced by recipient lymphocyte infusions lead to significant anti-tumour responses against different hosttype tumours. [21] [22] [23] A recent study provides evidence for the emergence of naturally elicited anti-leukemic CTL response in paediatric patients with AML in CR after chemotherapy or autologous BMT, and the proliferation of these CTL in patients with durable CR. 24 Even if we could not draw definitive conclusions in this very rare situation, this retrospective analysis does suggest that an efficient anti-tumour effect can be observed without a sustained donor chimerism and that the transient presence of donor T cells might indeed be sufficient to induce a clinically relevant graft-vs-tumour effect.
